Case Report

Malignant transformation of pleomorphic xanthoastrocytoma in pregnant patient: Clinical case and ethical dilemma

Jurica Marakovic1,2, Darko Chudy1,3, Danko Muller2,4, Damir Tomac1, Petar Marcinkovic1, Darko Oreskovic1, Andjelo Kastelancic1, Marina Raguz1

1Department of Neurosurgery, Dubrava University Hospital, 2School of Medicine University of Zagreb, 3Department of Surgery, School of Medicine University of Zagreb, 4Department of Pathology and Cytology, Dubrava University Hospital, Zagreb, Croatia

E-mail: Jurica Marakovic - juricam@kbd.hr; Darko Chudy - darko.chudy@gmail.com; Danko Muller - danko.mueller@yahoo.com; Damir Tomac - dtomac@kbd.hr; Petar Marcinkovic - petar.marcinkovic11@gmail.com; Darko Oreskovic - darkoreskov@gmail.com; Andjelo Kastelancic - andjelo.kastelancic@gmail.com; *Marina Raguz - marinaraguz@gmail.com

*Corresponding author:
Marina Raguz,
Department of Neurosurgery,
University Hospital Dubrava,
Zagreb, Croatia.
marinaraguz@gmail.com

Received : 07 February 2021
Accepted : 21 August 2021
Published : 20 September 2021

DOI
10.25259/SNI_120_2021

Quick Response Code:

INTRODUCTION

Pleomorphic xantho-astrocytoma (PXA) is a rare cerebral neoplasm first described in 1979 and added to the World Health Organization (WHO) classification of central nervous system neoplasms in 1993.[11,12] PXAs, an astrocytic tumors originates from subpial astrocytes account for <1% of astrocytic tumors.[2,8,20] It typically presents in childhood or early adult life, with a
peak incidence between 10 and 19 years of age. Clinical observations disclose common features of these neoplasms: patients are usually below 30 years of age; the tumors are located predominantly in the temporal and parietal regions, often involves the overlying leptomeninges; they have cystic appearance, and they are frequently superficially located. Epileptic seizures are a typical initial symptom, followed by slowly progressive, focal neurological deficits. Due to its rarity, etiology, natural history, and biologic behavior, are not completely explained. PXA has varied histologic appearance. Due to the pleomorphism, it usually histologically appears malignant, but the absence of the mitosis and necrosis classify PXA as a Grade II neoplasm, while PXA with anaplastic features is classified as WHO Grade III neoplasm. Two types of anaplastic PXA have been described previously: primary anaplastic process, in which malignant features are present, and secondary anaplastic process, in which malignant transformation occurs. Histological features characteristic for the anaplastic PXA are mitosis, focal necrosis, and endothelial proliferation. Furthermore, the histological features include spindle-shaped cells, pleomorphic cell population with hyperchromasia and multinucleated giant cells, lipid droplets in tumor cells, eosinophilic granular bodies, and a dense reticulin network. The histological differential diagnosis for the PXA includes glioblastoma, malignant fibrous histiocytoma, fibroxanthoma, xanthosarcoma anaplastic pilocytic astrocytoma, and ganglionic tumors. The surgical removal of the neoplasm is the main therapeutic approach. If the anaplastic PXA is confirmed, the adjuvant chemo or radiotherapy can be useful, but the standard postoperative adjuvant therapy has still not been established. The interesting characteristic of this neoplasm is the relatively benign clinical behavior despite the histological pleomorphism. PXA without anaplastic features has a favorable prognosis and is generally associated with a good outcome with 75–80% overall survival rates and 15–30% recurrence rate after 5 years, following primary resection. According to the literature, 6–9% of typical PXA cases undergo malignant transformation into an anaplastic PXA. Malignant transformation is possible evolution of PXA, but there are no definite predictors of transformation. However, the higher number of the mitosis and the higher proliferation index seems to be related with increased probability of anaplastic transformation.

Occurrence of malignant brain tumors, namely, gliomas, diagnosed during pregnancy is quite rare, and there are several cases describing treating management, along with associated ethical dilemmas. There are no clear guidelines on treatment of a pregnant patient with gliomas, and the management strategy primarily depends only on case reports and small series in the literature. Hereby, we present a case of pregnant patient diagnosed with PXA that malignantly transformed to glioblastoma after surgical treatment and delivery of a child. Best to our knowledge, there has been no cases of malignant transformation of PXA to glioblastoma in pregnant patient.

CASE DESCRIPTION

History

A 28-year-old female patient was presented with a newly onset of headache, nausea, and right-sided hemiparesis. No other symptoms nor neurological deficits were presented. The patient was 21 week pregnant. Patient had a history of grand mal epilepsy attacks and was on antiepileptic therapy since age of 12 till the age of 18; during that period, no neuroradiological scanning was performed. At the admission, carbamazepine therapy was prescribed by the neurologist. Initial magnetic resonance imaging (MRI) revealed cystic mass in the left frontal region; due to pregnancy intravenous contrast was not applied [Figure 1].

Operations and treatment

Patient underwent small left frontal osteoplastic craniotomy, evacuation of the cyst and the tumor biopsy under local anesthesia. Surgery went without any complications. Patient recovered uneventfully. Tissue samples acquired during the surgical procedure underwent pathohistological analysis. Since the pathohistological characteristics were challenging to interpret, both domestic and respectable foreign institutions were contacted and participated in analysis. Three types of tumor cells were noted; the most remarkable features are large polymorphic bizarre cells with large nuclei and atypical mitotic figures, followed by cells with empty vacuoles and small astrocytic like neoplastic cells in an epithelioid pattern. Parts of tumor consisted some reticulin network. A few pre-necrotic areas, collections of perivascular lymphocytes and areas with a slightly larger glial spindle cells were described. Microvascular proliferation was not observed. The tumor was strongly positive for SMI31 and 32 and SMI113, beta catenin, mainly on cellular membrane, as well as all neurofilament markers. Proliferation index was positive in 3–5% of the small cells, while in large, bizarre cells was around 30%. In addition, absence of the BRAF V600E mutation was showed. According to the WHO classification tumor tissue corresponded to an anaplastic PXA Grade III [Figure 2].

The patient, her husband and family were informed about diagnosis and treatment methods, including both chemo and radiotherapy, as well as the risk and anticipated complications that might happen during pregnancy. It was stated by the patient and her husband that they would like to carry on with the current pregnancy. New MRI was performed [Figure 3]. Two weeks after initial biopsy, open surgery along with gross
total tumor removal was performed. Surgery went without complications and no neurological deficits were found postoperatively. Tissue samples acquired during the surgical procedure underwent pathohistological analysis revealing the same diagnosis, PXA.

Six months later, after childbirth, control MRI revealed a supratentorial recurrent tumor mass in left frontal region with the cystic part in the superior frontal gyrus. After the administration of intravenous contrast, the mass showed heterogeneous enhancement [Figure 4]. Patient underwent frontoparietal osteoplastic re-craniotomy and the tumor mass was completely removed. Surgery went without complications. A control MRI revealed a satisfactory finding, without any signs of ischemia, hemorrhage, or residual tumor. Patient recovered uneventfully. Tissue samples acquired during the surgical procedure underwent pathohistological analysis. In the tumor tissue taken from 4 cm below the cortex, polymorphic atypical glial cells with high mitotic activity and microvascular proliferation were described. Tumor tissue from the paraventricular frontal left area showed anaplastic astroglial cells with high mitotic activity and proliferation index higher than 50%. According to the WHO classification tumor tissue corresponded to a glioblastoma WHO Grade IV [Figure 5].

An oncologist was consulted. According to protocol for the treatment of primary glioma patient was referred to fractionated external beam radiation therapy of the whole brain (60 Gy) and temozolomide therapy. Furthermore, chemotherapy was administered. Two months after mentioned therapy, patient was further treated with monochemotherapy (temozolomide).
Postoperative course

A year later, control MRI revealed postoperative cavity with pathological area of contrast accumulation in the posterior part, neuroradiologically described as probably residue of the tumor. No significant changes comparing to the previous MRI were found. Same findings were described yet on another control MRI after 6 months. Two year after initial diagnosis was established, patient, according to her husband’s claims, became disoriented and disturbed. She complained on a headache in frontal region. No significant neurological deficit was found. Computerized tomography scan showed hypodense zones in both, left and right, frontal region and in the left temporal region and narrowed lateral and third ventricles. MRI revealed expansive neoplastic masses in the right frontal region, left frontal region with rectal and orbital gyri and pericallosal area affected and in the left temporal region, along with necrotic zones [Figure 6]. Neurosurgical treatment was no indicated. Antiedematous therapy was prescribed, and further follow-up by oncologist was recommended. Unfortunately, during oncological treatment, patient died.

DISCUSSION

Best to our knowledge, there has been no cases of malignant transformation of PXA to glioblastoma in pregnant patient in the literature. Several cases and small series describe individual approach in treating pregnant patients with glioma, but still, clear guidelines have not been established.[1,4,19] In case like ours, when pregnant patient is presented with brain tumor whose etiology and biology are not completely understood, it is very challenging to decide course of treatment. In addition, ethical aspects of pregnancy should be taken into account.

Neurobiology of PXA is still controversial. Immunohistochemical studies support astrocytic and neuronal differentiation of PXA and indicate that PXA is probably a developmental neuroglial tumor with prominent glioproliferative changes associated with focal cortical dysplasia.[5] Comparative genetic analysis of PXA and invasive gliomas has demonstrated that the normal P53 alterations that occur within invasive gliomas are present in <2% of PXAs; in addition, the typical chromosomal and genetic aberrations associated with diffuse infiltrating astrocytic and oligodendrogliomal gliomas are different from PXAs.[10] These genetic differences likely contribute to the favorable behavior of PXAs. Distinguishing between patients with PXA who have a good prognosis and those at risk for early progression is very important for the clinical management of PXA. Recently, the significance of the mitotic index, the presence of necrosis, and the extent of resection were analyzed. It was found that the mitotic index and the extent of resection were the main predictors for recurrence-free survival and overall survival rates.[14] Since grading scheme was previously proposed, several authors question whether specific histological factors are reliable predictors of future biological behavior.[13] Various molecular genetic changes are associated with PXA: the TP53 tumor suppressor genes, CDKN2A, CDK4, MDM2, and EGFR genes are well known to occur in diffuse infiltrating astrocytic glioma.

Figure 5: Microphotography of a pathohistological section showing histological and immunohistochemical features of a tumorous tissue stained with (a) hematoxylin and eosin, original magnification of ×100, (b) synuclein, original magnification of ×100, (c) proliferation index Ki67, original magnification of ×200. Tumor consisted out of atypical astroglial cells and high mitotic activity. Extensive microvascular proliferation of individual blood vessels was described, as well as focal points of tumor necrosis. Ki67 proliferation index higher was than 50%. According to the WHO classification, it corresponded glioblastoma multiforme, WHO Grade IV.

Figure 4: Control brain MRI, 6 months after initial diagnosis, after childbirth revealed a supratentorial recurrent tumor mass in the left frontal region with the cystic part in the superior frontal gyrus, presented on T1-weighted image with contrast enhancement on coronal (a) and axial plain (b).
including anaplastic astrocytoma and glioblastoma but are not involved in the pathogenesis of PXA. These genetic differences seem to be responsible for the distinct biological behavior of PXA.

According to the literature, PXA WHO Grade II behaves aggressively, recurring more frequently. During recurrence, its malignant potential is greater. Progression from the WHO Grade II to the WHO Grade IV has been previously described, frequently subsequently, but sometimes directly from Grade II to Grade IV. The standard therapy management is not yet established. Several studies showed that surgery is the most important therapeutic approach for the PXA. In addition, surgery is an option and craniotomy can be safely performed during pregnancy, particularly early trimester. If the pathohistology confirm the diagnosis of the anaplastic PXA, adjuvant radio or chemotherapy may be useful, although their benefit is still questionable. The administration of chemotherapy during pregnancy is risky and can induce harmful effects on both the mother and the fetus. The mother risk includes spontaneous abortion and sterility, while fetal expected problems include carcinogenesis, developmental delay, and potential congenital anomalies. Alkylating agents, temozolomide, procarbazine and vincristine, cross the placenta, therefore, fetal toxicity can happen.

Due to very limited data and only few reported cases in the literature, we used the best available medical evidence to treat this patient. The multidisciplinary team which included the neurosurgeon, oncologist, and obstetrician discussed with the family all the risks and benefits of the pregnancy, the natural history of the disease and the possible outcome as well as the available treatment options. Following the course of pregnancy and knowing the patient and husband wishes, the risk of pregnancy versus benefits was fully explained. It was decided to fully support the mother during her pregnancy. Unfortunately, only 6 months after childbirth, MRI revealed recurrent tumor, and pathohistological diagnosis confirmed glioblastoma. Therefore, another gross total resection was performed, and oncologic treatment was administrated including both radio and chemo adjuvant therapy followed by monochemotherapy treatment with temozolomide, like presented in the literature.

**CONCLUSION**

The rarity of PXA demands neuropathologic experience to find the correct diagnosis, since misinterpretation might cause harmful therapeutically decisions. A close follow-up is needed in order to detect any recurrence with malignant transformation. Furthermore, PXA probably originates in genetic changes which lead to its unpredictable biological behavior. Further molecular studies are necessary in order to elucidate the malignant transformation cascade in PXAs and eventually allow for genetic testing of these tumors after initial resection to provide insight on prognosis and need for adjuvant therapy. PXA diagnosis in pregnancy is a medical and ethical dilemma and generally carries a variable prognosis due to tumor pleomorphism. The multidisciplinary approach and frequent family counseling.

Figure 6: (a-f) Control MRI 2 years after initial diagnosis revealed expansive neoplastic masses in the right frontal region, left frontal region with rectal and orbital gyri and pericallosal area affected and in left temporal region, along with necrotic zones.
are important factors for managing patient and potentially successful treatment outcome.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent. Patients family has given informed consent for participation in this paper.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Al-Rasheedy IM, Al-Hameed FM. Advanced case of glioblastoma multiforme and pregnancy: An ethical dilemma. Neurosciences (Riyadh) 2015;20:388-91.
2. Binesh F, Akhavan A, Navabii H. Pleomorphic xanthoastrocytoma with malignant transformation and multiple recurrences in an Iranian girl. BMJ Case Rep 2012;2012:bcr1220115372.
3. Chakrabarty A, Mitchell P, Bridges LR, Franks AJ. Malignant transformation in pleomorphic xanthoastrocytoma—a report of two cases. Br J Neurosurg 1999;13:516-9.
4. Flechl B, Hassler MR, Kopetzky G, Balcke P, Kurz C, Marosi C. Case report: Pregnancy in a patient with recurrent glioblastoma. F1000Res 2013;2:246.
5. Fouladi M, Jenkins J, Burger P, Langston J, Merchant T, Heideman R et al. Pleomorphic xanthoastrocytoma: Favorable outcome after complete surgical resection. Neuro Oncol 2001;3:184-92.
6. Furuta T, Miyoshi H, Komaki S, Arakawa F, Morioka M, Ohshima K et al. Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma. Neuropathology 2018;38:218-27.
7. Gelpi E, Popovic M, Preusser M, Budka H, Hainfellner J. Pleomorphic xanthoastrocytoma with anaplastic features presenting without GFAP immunoreactivity: Implications for differential diagnosis. Neuropathology 2005;25:241-6.
8. Ida CM, Rodriguez FJ, Burger PC, Caron AA, Jenkins SM, Spears GM, et al. Pleomorphic xanthoastrocytoma: Natural history and long-term follow-up. Brain Pathol 2015;25:575-86.
9. Kanamori M, Suzuki H, Takei H, Sonoda Y, Uenohara H, Tominaga T. Malignant transformation of diffuse astrocytoma to glioblastoma associated with newly developed BRAF V600E mutation. Brain Tumor Pathol 2016;33:50-6.
10. Kaulich K, Blaschke B, Numann A, von Deimling A, Wiestler OD, Weber RG, et al. Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas. J Neuropathol Exp Neurol 2002;61:1092-9.
11. Kepes JJ, Rubinstein LJ, Eng LF. Pleomorphic xanthoastrocytoma: A distinctive meningocerebral glioma of young subjects with relatively favorable prognosis. A study of 12 cases. Cancer 1979;44:1839-52.
12. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol 2016;131:803-20.
13. Lubansu A, Rorive S, David P, Sariban E, Seligmann R, Brotchi J, et al. Cerebral anaplastic pleomorphic xanthoastrocytoma with meningeal dissemination at first presentation. Childs Nerv Syst 2004;20:119-22.
14. Macaulay RJ, Jay V, Hoffman HJ, Becker LE. Increased mitotic activity as a negative prognostic indicator in pleomorphic xanthoastrocytoma. Case report. J Neurosurg 1993;79:761-8.
15. Nakajima T, Kumabe T, Shamoto H, Watanabe M, Suzuki H, Tominaga T. Malignant transformation of pleomorphic xanthoastrocytoma. Acta Neurochir (Wien) 2006;148:67-1.
16. She D, Liu J, Xing Z, Zhang Y, Cao D, Zhang Z. MR imaging features of anaplastic pleomorphic xanthoastrocytoma mimicking high-grade astrocytoma. AJNR Am J Neuroradiol 2018;39:1446-52.
17. van Westrenen A, Senders JT, Martin E, DiRisio AC, Broekman ML. Clinical challenges of glioma and pregnancy: A systematic review. J Neurooncol 2018;139:1-11.
18. Vu TM, Liubinas SV, Gonzales M, Drummond KJ. Malignant potential of pleomorphic xanthoastrocytoma. J Clin Neurosci 2012;19:12-20.
19. Wu J, Ma YH, Wang TL. Glioma in the third trimester of pregnancy: Two cases and a review of the literature. Oncol Lett 2013;5:943-6.
20. Yamada SM, Murakami H, Tomita Y, Nakane M, Shibui S, Takahashi M, et al. Glioblastoma multiforme versus pleomorphic xanthoastrocytoma with anaplastic features in the pathological diagnosis: A case report. Diagn Pathol 2016;11:65.